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Role of IL-6 and Its Soluble Receptor
in Induction of Chemokines
and Leukocyte Recruitment
Maria Romano,*# Marina Sironi,*# Carlo Toniatti,³ et al., 1993). IL-6 target cells express on their surface a
low affinity receptor (IL-6R) devoid of transducing activ-Nadia Polentarutti,* Paolo Fruscella,* Pietro Ghezzi,*
ity. The complex IL-6±IL-6R induces the homodimeriza-Raffaella Faggioni,* Walter Luini,*
tion of a signal-transducing component, gp130, which isVictor van Hinsbergh,‖ Silvano Sozzani,*
also shared by IL-6-related cytokines such as leukemiaFederico Bussolino,§ Valeria Poli,³
inhibitory factor, oncostatin M, ciliary neurotrophic fac-Gennaro Ciliberto,³ and Alberto Mantovani*²
tor, and IL-11 (reviewed by Kishimoto et al., 1995). The*Istituto Ricerche Farmacologiche ªMario Negriº
gp130 dimer activates Jak kinase, followed by tyrosine-Milan
specific phosphorylation of APRF/STAT3 (signal trans-Italy
ducer and activator of transcription 3) and its transloca-²Department of Biotechnology
tion to the nucleus and the Ras±MAP kinase cascade,Section of Pathology and Immunology
whose ultimate substrate is NF-IL-6 (reviewed by Kishi-University of Brescia
moto et al., 1994, 1995).Italy
A soluble form of the IL-6R (sIL-6R) can be generated³Istituto di Ricerche di Biologia Molecolare
by shedding from the membrane-bound receptor pro-ªP. Angelettiº
tein (Mullberg et al., 1993) or by mRNA alternative splic-Rome
ing (Lust et al., 1992). sIL-6R is found in biological fluidsItaly
(Novick et al., 1989; Honda et al., 1992; Gaillard et al.,§Dipartimento di Genetica
1993; Frieling et al., 1995; De Benedetti et al., 1994). AsBiologia e Chimica Medica
the intracytoplasmic and transmembrane domains of IL-UniversitaÁ di Torino
6R do not play an essential role in signaling, the solubleTorino
form of IL-6R forms a complex with IL-6 in solution
Italy
and associates properly with gp130, thereby activating‖TNO±PG Gaubius Laboratory
signal transduction. The capacity of sIL-6R to confer
Leiden IL-6 responsiveness to a variety of cells that do not
The Netherlands express transmembrane IL-6R, but harbor only gp130,
is of physiological relevance. Indeed, elevated levels of
sIL-6R are found in serum (Novick et al., 1989; Honda
Summary et al., 1992; Gaillard et al., 1993; Frieling et al., 1995; De
Benedetti et al., 1994), and they may be responsible for
IL-62/2 mice showed impaired leukocyte accumulation chaperoning the cytokine and widening the spectrum
in subcutaneous air pouches. Defective leukocyte ac- of IL-6-responsive cells to those that do not express
cumulation was not due to a reduced migratorycapac- endogenous IL-6R mRNA.
ity of IL-62/2 leukocytes and was associated with a Endothelial cells (EC) play an important, active role in
reduced in situ production of chemokines. These ob- inflammatory and immune reactions. Their properties
servations led to a reexamination of the interaction of are profoundly altered by microbial products and cyto-
IL-6 with endothelial cells (EC). EC express only the kines, different polypeptide mediators eliciting distinct,
gp130 signal transducing chain and not the subunit- largely nonoverlapping sets of functions (Mantovani et
al., 1992; Pober and Cotran, 1990). EC, as well as otherspecific IL-6R and are therefore unresponsive to IL-6.
vascular elements, produce copious amounts of IL-6 inHowever, EC are responsive to a combination of IL-6
response to proinflammatory signals, including micro-and soluble IL-6R as measured by the activation of
bial products, IL-1, and tumor necrosis factor (TNF) (Sir-STAT3, chemokine expression, and augmentation of
oni et al., 1989; Jirik et al., 1989; Shalaby et al., 1989;ICAM-1. Activation by IL-6±IL-6R complexes was in-
Podor et al., 1989), as well as hypoxia (Yan et al., 1995).hibited by an IL-6 receptor antagonist and potentiated
It is not clear whether and how IL-6 affects the functionby a superagonist. Hence, in vivo and in vitro evidence
of normal vascular endothelium.supports the concept that the IL-6 system plays an
Several lines of evidence suggest that IL-6 may playunexpected positive role in local inflammatory reac-
a role in normal and neoplastic angiogenesis (Campbelltions by amplifying leukocyte recruitment.
et al., 1993; Motro et al., 1990; Andert et al., 1992).
IL-6 overexpression in the central nervous system ofIntroduction
transgenic mice correlates with a pronounced vasculari-
zation (Campbell et al., 1993). Furthermore, IL-6 mRNA is
Interleukin-6 (IL-6) is a multifunctional cytokine that sup-
expressed in EC during angiogenesis that accompanies
ports the differentiation of B cells, stimulates thrombo-
folliculogenesis and formation of maternal decidua (Mo-
poiesis and the synthesis of acute phase proteins, and tro et al., 1990). Stimulation of normal EC growth by IL-6
regulates bone resorption (Hirano et al., 1990; Kishimoto is controversial (Mantovani et al., 1992). Finally, IL-6 may
et al., 1995). IL-6 has also been implicated in the auto- participate in the regulation of the growth of Kaposi's
crine growth of myeloma (Kawano et al., 1988; Schwab sarcoma (Miles et al., 1990), a vascular tumor character-
et al., 1991) and leukemia cells (Biondi et al., 1989; Barut ized by prominent angiogenesis. Although IL-6 is pro-
duced in abundant amounts by EC exposed to inflam-
matory signals, it does not seem to play a role in the# These authors contributed equally to this work.
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Table 1. Defective Leukocyte Recruitment in IL-62/2 Mice
Volume of Total Leukocytes PGE2 TNF
Treatment Exudate (ml) (3106/ml) (pg/ml) (pg/ml)
IL-61/1 Saline 0.86 6 0.06 0.78 6 0.27 #20 #50
Carrageenan 1.26 6 0.19 11.88 6 4.9 420 6 230 173 6 120
CMC 1.02 6 0.15 2.01 6 0.3 NT NT
IL-1 0.92 6 0.1 7.27 6 0.89 NT NT
IL-62/2 Saline 0.90 6 0.04 1.12 6 0.30 #20 #50
Carrageenan 1.18 6 0.15 6.97 6 2.26** 475 6 179 301 6 204*
CMC 1.05 6 0.20 1.82 6 0.24 NT NT
IL-1 0.90 6 0.05 3.96 6 0.60** NT NT
We injected 1 ml of 1% carrageenan in sterile saline, 20 ng of human recombinant IL-1b in 1 ml of 0.5% sterile CMC, or the corresponding
vehicles into 6-day-old air pouches. Animals were sacrificed 4 hr (IL-1 treatment) or 24 hr later. Results are mean 6 SE of 5±17 different mice
per group. The percentage of leukocyte populations was similar in IL-61/1 and IL-62/2 mice, with, for instance, 39% polymorphonuclear
leukocytes, 39.5% monocytes, and 21.6% lymphocytes in carrageenan-injected IL-61/1 mice and 42.4%, 36%, and 21.6% for the same cells
in IL-62/2 mice. *p # 0.05; **p # 0.01, Student's t test IL-61/1 vs IL-62/2 that received the same treatment. NT, not tested.
activation of EC in a prothrombotic/proinflammatory that observed in wild-type mice (Figure 1). In addition,
when human IL-8 was injected into the air pouches asense, as assessed by addition of the recombinant cyto-
kine and use of blocking antibodies (Sironi et al., 1989; comparable number of cells was recovered from IL-62/2
and wild-type mice after 4 hr of treatment (10.8 6 1.8 3Podor et al., 1989).
The present study was prompted by in vivo observa- 106 and 11.5 6 2.2 3 106, respectively; n 5 5). Taken
together, these results rule out a defect in the chemotac-tions in IL-6 targeted mice. Unexpectedly, IL-62/2 mice
showed defective leukocyte recruitment associated tic responsiveness of leukocytes from IL-62/2 mice. On
the contrary, a defect in the local production of chemo-with defective chemokine production. These findings
were surprising given the capacity of IL-6 to inhibit IL-1 tactic factors was observed in IL-62/2 mice. Carra-
geenan pouch exudates from IL-62/2 mice showed aand TNF production and to protect against lipopolysac-
charide (LPS) toxicity (Barton and Jackson, 1993; Ad- strongly reduced in vitro chemotactic activity for PMN
and monocytes with respect to wild-type mice (Tableerka et al., 1989; Schindler et al., 1990; Arbo et al., 1990).
We therefore reexamined the interaction of IL-6 with EC,
which play a central role in the regulation of leukocyte
recruitment. We found that sIL-6R renders gp130-
expressing EC responsive to IL-6, with selective induc-
tion of chemokine production and ICAM-1 expression.
Thus, in vitro and in vivo evidence suggest that IL-6
plays an unexpected positive role in the regulation of
leukocyte recruitment and activates a unique pattern of
responses in EC.
Results
Defective Leukocyte Recruitment in IL-6
Targeted Mice
Injection of carrageenan in mouse air pouches induces
local leukocyte infiltration (Sin et al., 1989). Table 1
shows that this response was reduced to about 50% in
IL-62/2 mice compared with wild-type mice. In contrast,
TNF and PGE2 levels in the pouch inflammatoryexudates
were not modified or slightly increased as previously
described (Fattori et al., 1994). Defective leukocyte re-
cruitment was observed as early as 8 hr after carra-
geenan treatment and encompassed all white blood cell
types (Table 1). A similar defect in leukocyte recruitment
was evident when IL-1 was used as an eliciting agent
Figure 1. In Vitro Responsiveness of IL-61/1 and IL-62/2 Leukocytes(Table 1). To elucidate the mechanism(s) underlying this
to Chemoattractantsdefective response, we evaluated the chemotactic activ-
Chemotactic activity for mouse macrophages (upper panel) or PMNity of phagocytic cells from IL-62/2 in vitro and in vivo.
(lower panel) was tested as detailed in Experimental Procedures.Thioglycollate-elicited peritoneal polymorphonuclear
Exudateswere tested undiluted in a microchemotaxis assay. Results
leukocytes (PMN) or macrophages from IL-62/2 mice are expressed as number of cells migrated in five high power oil
showed a chemotactic response toC5a, IL-8 and, mono- immersion fields and are the average values of five (upper) and three
(lower) different animals tested in triplicate.cyte chemotactic protein 1 (MCP-1) comparable with
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Table 2. Reconstitution of Leukocyte Recruitment in IL-62/2 Mice by Local Injection of IL-6 or IL-8
In Vitro Chemotaxis
Carrageenan Cytokine Total Leukocytes MCP-1
(1 ml) (1 mg per mouse) (3106/ml) (ng/ml) Monocyte PMN
Experiment 1
IL-61/1 1 Ð 13.6 6 2.8 24.6 6 3.0 96 6 2 24.6 6 3
IL-62/2 1 Ð 7.5 6 2.2* 13.2 6 4.6* 26 6 2* 4.5 6 3*
IL-61/1 1 IL-6 10.2 6 3.1 17.4 6 3.0 NT 34.2 6 6
IL-62/2 1 IL-6 11.6 6 2.3a 27.0 6 8.0a NT 35.5 6 6a
Experiment 2
IL-61/1 1 Ð 7.09 6 1.7 NT NT NT
IL-62/2 1 Ð 3.53 6 0.6** NT NT NT
IL-61/1 2 IL-8 10.8 6 1.8 NT NT NT
IL-62/2 2 IL-8 11.5 6 2.2 NT NT NT
IL-61/1 1 IL-8 15.8 6 2.5 NT NT NT
IL-62/2 1 IL-8 17.9 6 4.7a NT NT NT
We injected 1 ml of 1% carrageenan in sterile saline into 6-day-old air pouches, alone or together with IL-6, IL-8 (1 mg/mouse), or vehicle.
Animals (at least five per group) were sacrificed 24 hr later. The pouch fluid was collected, and MCP-1 levels and chemotactic activity for
monocytes or PMN was assessed by ELISA and bioassay, respectively. PMN and monocyte migration is expressed as number of cells migrated
above basal activity (migration against medium). Results are means 6 SE of one experiment (n 5 5 mice tested individually) tested at one
optimal dilution (1:2 and 1:9 for PMN and monocytes, respectively) representative of three dilutions. The number of cells accumulated in
response to saline alone was similar (#1 3 106, see Table 1) in 1/1 and 2/2 mice and it is not presented. NT, not tested.
*p # 0.05, **p # 0.01 Student's t test IL-61/1 versus IL-62/2 that received the same treatment.
a p # 0.05 versus IL-62/2 mice injected with carrageenan alone.
2). In parallel, lower levels (z50%) of immunoreactive blot analysis in EC, whereas they were evident in U937
cells used as positive control. IL-6 and sIL-6R, alone or inMCP-1, a monocyte chemotacticagonist, were detected
in the same exudates (Table 2). Finally, it was observed combination, did not affect gp130 and IL-6R expression
(Figure 3).that the injection of 1 mg per mouse of human IL-6 into
the pouches of IL-62/2 mice was able to restore fully
the defect in both leukocyte recruitment and chemokine Induction of Chemokine Production
by IL-6 and sIL-6Rproduction. The local injection of IL-6 did not have any
effect in wild-type mice when injected alone (data not The absence of IL-6R mRNA expression might well ex-
plain the lack of a direct effect of the cytokine in EC;shown) or with carrageenan (Table 2). Boiled IL-6 had
no effect (data not shown). When IL-8 was injected lo- however, it does not exclude the possibility of EC re-
sponsiveness to the combined action of the IL-6±sIL-Rcally, with or without carrageenan, leukocyte accumula-
tion was similar in IL-61/1 and IL-62/2 mice; in particular, complex. We therefore examined the effect of IL-6 and
sIL-6R on EC. In agreement with previous observationsafter coadministration of IL-8, 2/2 and 1/1 mice
showed similar number of leukocytes (Table 2). As we (Sica et al., 1990; Rollins et al., 1990), IL-6 did not induce
did not have access to IL-6R2/2 mice, the effect of anti-
IL-6R monoclonal antibody (MAb) was studied in an
effort toassess further the in vivo role of IL-6 in leukocyte
recruitment. As shown in Figure 2, anti-IL-6R MAb, but
not an irrelevant MAb, inhibited leukocyte accumulation
in carrageenan-injected air pouches to an extent com-
parable with the defect seen in IL-62/2 mice.
Expression of IL-6R and gp130 in EC
The results obtained in IL-62/2 mice pointed to a role of
this cytokine in the regulation of leukocyte recruitment
via stimulation of chemokine production. These results
were surprising, since IL-6 is not chemotactic per se, in
previous studies we had found no direct effect of IL-6
on the production of proinflammatory molecules and
chemotactic factors by EC (Sironi et al., 1989), and there Figure 2. Effect of Anti-IL-6R MAb on Leukocyte Recruitment
is evidence for anti-inflammatory activity of this cytokine Normal mice (IL-61/1) were treated intravenously with 100 mg of anti-
IL-6R MAb in 0.25 ml of saline or the same amount of an irrelevant(Barton and Jackson, 1993; Aderka et al., 1989; Schin-
anti-IL-4 MAb. After 24 hr, 20 ng of human recombinant IL-1 in 1dler et al., 1990). We therefore reexamined the inter-
ml of 0.5% carboxymethylcellulose was injected in 6-day-old airaction of IL-6 with vascular EC. We first studied EC
pouches. Animals were sacrificed 4 hr after IL-1 treatment. By wayexpression of the two polypeptides that assemble the
of comparison, IL-62/2 mice were tested in parallel. Results are
functional IL-6 receptor. As shown in Figure 3, EC ex- expressed as number of cells (3 106) migrated in pouches. Asterisk,
pressed abundant amounts of gp130 transcripts. In con- p # 0.05, double asterisk, p # 0.01, according to Duncan's test for
multiple comparisons.trast, IL-6R transcripts were undetectable by Northern
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Figure 3. Expression of IL-6R and gp130
in EC
Northern blot analysis of the IL-6R (A) or
gp130 expression (B) in EC cultured for 4 hr
with IL-6 (10 ng/ml) with or without sIL-6R.
U937 cells were used as positive control. The
lower panels show hybridization with b-actin.
MCP-1 production in EC. Similarly, sIL-6R (up to 100 induced low but appreciable amounts of IL-6 itself (Fig-
ure 4C). When different concentrations of sIL-6R wereng/ml, 1.89 3 1029 M) alone did not elicit measurable
responses in EC. In contrast, combinations of IL-6 and used in the range of 10±500 ng/ml (Figure 5C), which
spans the physiological levels of sIL-6R found in humansIL-6R induced substantial amounts of MCP-1, with
17.58 6 3.69 ng/ml in 24 hr (mean 6 standard error of
11 experiments) compared with 2.16 6 0.38 ng/ml of
medium control (p , 0.001) (Figure 4A). Similar results
were obtained when IL-8 was measured (Figure 4B).
Interestingly, the combination of IL-6 and sIL-6R also
Figure 5. Anti-IL-6 Antibodies and Heat-Inhibited Induction of
MCP-1 by Combined IL-6 and sIL-6R
EC were cultured for 24 hr with IL-6 (10 ng/ml) with or without sIL-
6R (100 ng/ml), in the presence of irrelevant MAb or 250 ng/ml
neutralizing MAb against IL-6 (A) or with heat-inactivated sIL-6R (B).
Figure 4. Induction of Cytokine Production by Combined IL-6 and MCP-1 was measured by ELISA. In (A), closed column, control;
sIL-6R hatched column, control MAb; open column, anti-IL-6. In (B), closed
column, control SN; densely hatched column, heat-inactivated con-EC were cultured for 24 hr with IL-6 (10 ng/ml) with or without sIL-
6R (100 ng/ml). sIL-6R was the supernatant from CHO-transfected trol SN; hatched column, sIL-6R; open column, heat-inactivated sIL-
6R. In (C), EC were cultured for 24 hr with graded concentrationscells, and an appropiate control (supernatant [SN]) was used. MCP-1
(A) and IL-8 (B) were measured by ELISA. To investigate induction of sIL-6R (10±500 ng/ml) with 10 ng/ml of IL-6. MCP-1 was measured
by ELISA. Open circles, control SN; closed circles sIL-6R. Doubleof IL-6 (C), after 24 hr incubation with stimuli (see above) cells were
washed and the incubation was carried on for a further 24 hr in the asterisk, p # 0.01, Student t test anti-IL-6 MAb versus irrelevant
MAb (A); IL-6R versus heat inactivated IL-6R (B).absence of stimuli; IL-6 was measured as hybridoma growth factor.
IL-6 and Leukocyte Recruitment
319
Figure 6. Induction of Chemokine mRNA by Combined IL-6 and
sIL-6R
EC were cultured for 4 hr with IL-6 (10 ng/ml) with or without sIL-
6R (100 ng/ml) and gene expression was assessed by Northern blot
analysis with total RNA using an MCP-1 and an MCP-3 probe. The
amount of RNA blotted was checked by ethidium bromide staining
of the membrane and by hybridization with b-actin. Figure 7. IL-6 plus sIL6R Activate STAT3 DNA Binding Activity in EC
EC (1 3 106) were treated for 10 min with IL-6 (10 ng/ml) in the
presence or absence of 100 ng/ml of sIL-6R. At the end of the
incubation time, nuclear extracts were prepared and 3 mg was usedsera (z50 ng/ml) (Novick et al., 1989; Honda et al., 1992;
to monitor the binding of STAT3 to the 32P-labeled SIE probe (seeGaillard et al., 1993; Frieling et al., 1995; De Benedetti
Experimental Procedures). As a control, nuclear extract from un-et al., 1994), induction of MCP-1 was observed. Boiling
treated EC was used.
of sIL-6R, as well as anti-IL-6 antibodies, completely
abolished the induction of MCP-1 by combined IL-6 and
sIL-6R (Figure 5). Induction of cytokine production by affinity IL-6 variant mutated in the predicted IL-6R bind-
combined IL-6 and sIL-6R was associated with in- ing interface; in particular, it carries three amino acid
creased steady-state levels of transcripts encoding substitutions in the D helix (Q175I/S176R/Q183A) and
MCP-1 (Figure 6). IL-6 and sIL-6R alone were also com- two in the AB loop (Q75Y/S76K). D-6 binds IL-6R z40-
pletely inactive at the mRNA level. By Northern blot fold tighter than wild-type IL-6 and displays a strongly
analysis, IL-6±IL-6R complexes also induced low but increased bioactivity with respect to wild-type IL-6, es-
appreciable expression of MCP-3 (Figure 6). In con- pecially when used in conjuction with sIL-6R on cells
trast, groa, IP10, Rantes, and MIP-1a were not induced expressing gp130 only (Toniatti et al., 1996). As shown
at the mRNA or protein level (data not shown). in Figure 8, D-6 alone did not induce responses in EC,
but when combined with sIL-6R elicited a substantially
Activation of STAT3 in EC by Combined greater level of MCP-1 production than IL-6 itself. Sant7
IL-6 and sIL-6R is an IL-6 variant that behaves as a potent receptor
One of the earliest steps in the gp130-dependent signal antagonist; in fact, it not only contains the same su-
transduction pathway is the phosphorylation of the la- perbinder substitutions present in D-6, but also two
tent cytoplasmic transcription factor STAT3 (also called other groups of substitutions, in the A and C helices
acute-phase response factor [APRF]) by kinases of the (Y31D/G35F/S118R/V121D) and in theAB loop (L57/E59/
Jak/Tyk family. Upon phosphorylation, STAT3 acquires L62W), respectively, that totally abolish the interaction
the capability to bind its DNA target sequence and to with gp130 (Savino et al., 1994; Sporeno et al., 1996;
activate transcription of downstream genes (Akira et al., Toniatti et al., 1996). Sant7 is therefore able to bind
1994; Zhong et al., 1994). This can be easily monitored IL-6R more efficiently than wild-type IL-6, but cannot
by electrophoretic mobility shift assay (EMSA), which activate intracellular signaling (Sporeno et al., 1996).
constitutes the most sensitive assay to monitor the acti- Figure 8 indicates that Sant7 completely inhibited the
vation of intracellular signaling by IL-6-type cytokines. induction of MCP-1 by the combination of IL-6 and sIL-
EC were treated for 10 min with IL-6 in the presence or 6R as well as of D-6 and sIL-6R.
absence of sIL-6R. Nuclear extracts were prepared and
the activation of STAT3 was monitored by EMSA. As Selectivity of Chemokine Induction
shown in Figure 7, a clear induction of STAT3 binding As reported in Table 3, IL-6 alone or in the presence of
activity was only observed when EC were treated with sIL-6R did not modify a series of EC functions, including
IL-6 in conjunction with sIL-6R. No activation was ob- procoagulant activity, production of platelet-activating
served with either the cytokine or sIL-6R alone. factor (PAF), NOS activity, proliferation, and expression
of the E-selectin and VCAM-1 cell surface adhesion mol-
ecules. CD31 was also not modified by IL-6±IL-6R com-Effect of IL-6 Muteins with Agonistic
or Antagonistic Activity plexes (data not shown). In contrast, in four experiments,
IL-6±IL-6R complexes augmented ICAM-1 expression,A collection of human IL-6 mutants with receptor agonis-
tic or antagonistic properties has been recently gener- though at levels considerably lower than those induced
by IL-1 (Table 3) or TNF (data not shown). Table 3 showsated (Toniatti et al., 1996; Sporeno et al., 1996). It was
therefore of interest to compare the activity of these enzyme-linked immunosorbent assay (ELISA) data (one
experiment of four performed), but similar results weremutants on EC with that of wild-type IL-6. D-6 is a high
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appreciable chemokine production in PMN, peripheral
blood mononuclear cells, one fibroblast, and one kera-
tinocyte (E11) line (data not shown).
Discussion
The present study was based on the observation that
IL-62/2 mice show defective leukocyte (monocytes,
PMN, and lymphocytes) recruitment in air pouches in-
jected with inflammatory signals (carrageenan and IL-1).
Defective recruitment in IL-62/2 mice was reversed by
injection of IL-6 and associated with lower levels of
chemotactic activity and immunoreactive MCP-1 in the
pouch. Leukocytes from IL-6 targeted mice show normal
responsiveness to chemoattractants in vitro and in vivo.
Consistent with a role of IL-6 in leukocyte recruitment,
anti-IL-6RMAb reduced leukocyte accumulation in wild-
type mice to an extent similar to that seen in IL-62/2
mice. These results indicated that IL-6 plays a role in
vivo in amplifying leukocyte accumulation at sites of
inflammation, at least in part by augmenting the local
production of chemokines. In keeping with this concept,
defective macrophage accumulation was recently ob-
served in IL-62/2 BALB/c mice injected intraperitoneally
with pristane (V. P. and G. C., unpublished data) and
Figure 8. Effect of IL-6 Muteins with Agonist or Antagonist Activity islet-specific overexpression of IL-6 in the pancreas of
on EC Activation transgenic mice promotes local inflammation (Campbell
(A) EC were cultured for 24 hr with IL-6 (10 ng/ml) or superagonist et al., 1994; Di Cosmo et al., 1994).
IL-6 (D6, 10 ng/ml), with or without sIL-6R (100 ng/ml). MCP-1 was Vascular endothelium plays a central role in the regu-
measured by ELISA.
lation of leukocyte extravasation and produces abun-(B) EC were cultured for 24 hr with IL-6 (10 ng/ml) with or without
dant amounts of chemokines, including MCP-1 (Sica etsIL-6R (100 ng/ml) in the presence or absence of an IL-6 antagonist
al., 1990; Rollins et al., 1990; Mantovani et al., 1992;(Sant7, 1 mg/ml). MCP-1 was measured by ELISA.
Pober and Cotran, 1990). However, by immunohisto-
chemistry we did not obtain unequivocal evidence that
the difference between IL-62/2 and IL-61/1 mice was dueobtained by fluorescence-activated cell sorter analysis
(one experiment; datanot shown). The results discussed to vascular endothelium (A. Stoppacciaro, unpublished
data). This failure most likely reflects the fact that theso far were obtained using human umbilical vein EC
(HUVEC) as a source of EC. Similar induction of MCP-1 defect is partial (approximately 40%±50% in terms of
accumulated leukocytes and chemokines) and that thewas observed when iliac artery EC or foreskin microvas-
cular EC were used (data not shown). In contrast, under technique is not quantitative. As separationand immedi-
ate testing of pouch vascular cells is not possible, wethese conditions, IL-6±IL-6R complexes did not elicit
Table 3. Selectivity of Induction of Chemokine Production by Combined IL-6 and sIL-6R
MCP-1 Procoagulant Proliferation ICAM-1 E-Selectin VCAM-1 PAFa NOSb
Stimuli (ng/ml) Activity (s) (OD) (OD) (OD) (OD) (pmol) (pmol)
Control 1.99 6 0.11 .200 0.39 6 0.04 0.2001 6 0.01 0.01 6 0.01 0.01 6 0.01 0.25 6 0.02 0.01 6 0.01
sIL-6R 2.16 6 0.12 .200 0.38 6 0.04 0.215 6 0.01 0.01 6 0.01 0.01 6 0.01 0.29 6 0.06 0.02 6 0.01
IL-6 2.13 6 0.12 .200 0.36 6 0.02 0.242 6 0.01 0.03 6 0.01 0.01 6 0.01 0.26 6 0.05 0.04 6 0.01
sIL-6R plus IL-6 10.19 6 0.92* .200 0.41 6 0.04 0.391 6 0.01* 0.03 6 0.01 0.04 6 0.02 0.23 6 0.05 0.02 6 0.01
IL-1 22.63 6 0.71* 47 6 0.5* nd 0.801 6 0.02 0.55 6 1.01* 0.32 6 0.01* nd nd
bFGF nd nd 0.807 6 0.03* nd nd nd nd nd
TNF nd nd nd nd nd nd 2.15 6 0.80* nd
IL-1 plus TNF nd nd nd nd nd nd nd 2.30 6 0.6*
plus IFng
EC were cultured with IL-6 (10 ng/ml; for PAF and NOS induction 50 ng/ml were used) and sIL-6R (100 ng/ml; for PAF and NOS induction
500 ng/ml were used), and various responses were measured. IL-1 (1 ng/ml), basic fibroblast growth factor (bFGF; 3 ng/ml), TNF (20 ng/ml),
and IFNg (500 U/ml) served as positive controls. The various endpoints were measured at different times: PCA and PAF, 4 hr; E-selectin, 6
hr; MCP-1, ICAM-1, VCAM-1, and NOS, 24 hr; proliferation, 3 days. Induction of ICAM-1 by IL-6±IL-6R complexes was observed in four
experiments using ELISA and one using FACS. OD, optical density; nd, not determined.
a Picomoles per 5 3 105 cells.
b Picomoles of citrulline per minute per milligram of protein.
* p , 0.01, Dunnet's test versus control.
IL-6 and Leukocyte Recruitment
321
examined chemokine release in vitro from aortic vascu- 1991; Brown et al., 1991; Sironi et al., 1994). IL-6 may
play a role in normal and neoplastic angiogenesislar tissue (see Experimental Procedures) of IL-1-injected
mice (n 5 3): MCP-1 release was 4.46 6 0.8 and 2.76 6 (Campbell et al., 1993; Motro et al., 1990; Andert et
al., 1992), but by itself was generally found inactive on0.4 ng/ml for IL-61/1 and IL-62/2 mice, respectively. We
therefore reexamined the interaction of IL-6 with vascu- normal HUVEC (Sironi et al., 1989; Podor et al., 1989).
The results reported here showing that IL-6 in concertlar endothelium in vitro. We found that EC express
gp130, but not the IL-6R gp80. Accordingly, they did with sIL-6R activates EC suggest that in vivo, where sIL-
6R is present, the various inducers mentioned abovenot respond to IL-6 or to a mutated superagonist, in
agreement with previous observations (Sironi et al., may activate an autocrine amplification pathway of EC
activation. If this is the case, IL-6 blocking agents like1989; Podor et al., 1989). However, when sIL-6R was
combined with IL-6, induction of MCP-1 and IL-8 pro- Sant7 may be expected to exert anti-inflammatory activ-
ity in vivo by decreasing leukocyte recruitment. The spe-duction were consistently observed. sIL-6R isgenerated
by enzymatic cleavage or alternative splicing and is cies specificity of Sant7 on the human receptor system
prevents testing this therapeutic hypothesis in mousefound in the circulation or in biological fluids (Mullberg
et al., 1993; Lust et al., 1992). For instance, in normal models presently available.
IL-6 is a major modulator of acute-phase gene expres-individuals sIL-6R was found in serum and urine (Novick
et al., 1989; Honda et al., 1992). Augmented sIL-6R se- sion during acute and chronic inflammation (Hirano et
al., 1990; Kishimoto et al., 1995). Indeed, IL-6-deficientrum levels were found in patients with rheumatoid arthri-
tis (De Benedetti et al., 1994), monoclonal gammopathy mice show impared acute-phase responses (Fattori et
al., 1994; Kopf et al., 1994; Fantuzzi and Dinarello, 1996;(Gaillard et al., 1993), and HIV infection (Honda et al.,
1992), while they were decreased during sepsis (Frieling Tanaka et al., 1995), and this was best observed after
local injection of inflammatory agents (e.g., turpentine).et al., 1995). sIL-6R was also found in synovial fluids of
patients with rheumatoid arthritis (De Benedetti et al., On the contrary, IL-62/2 mice challenged with a systemic
stimulus such as LPS showed a virtually normal pattern1994). In the present study, sIL-6R acted in concert with
IL-6 on EC at concentrations of 10±500 ng/ml (1.89 3 of acute-phase gene induction (Kopf et al., 1994; Fan-
tuzzi and Dinarello, 1996). We speculate that this appar-10210 to 9.45 3 1029 M). These concentrations are in the
same range as those measured in biological fluids. Thus, ent discrepancy may in part reflect the role of IL-6 in
amplifying recruitment of leukocytes at sites of inflam-sIL-6R, at physiological levels (Novick et al., 1989;
Honda et al., 1992; Gaillard et al., 1993; Frieling et al., mation, which in turn produces various inducers of the
acute-phase response. In the same vein, IL-62/2 mice1995; De Benedetti et al., 1994), renders EC responsive
to IL-6 in terms of chemokine expression and release. show augmented susceptibility to certain infectious
agents (Romani et al., 1996; Dalrymple et al., 1995). ItResults suggest that IL-6 may act as an anti-inflamma-
tory mediator (Barton and Jackson, 1993; Aderka et al., is tempting to speculate that defective leukocyte recruit-
ment contributes to impaired resistance to microbal1989; Schindler et al., 1990; Arbo et al., 1990). IL-6 sup-
pressed LPS-induced production of IL-1 and TNF in agents.
macrophages in vitro and in LPS-treated mice in vivo
(Barton and Jackson, 1993; Aderka et al., 1989; Schin- Experimental Procedures
dler et al., 1990; Arbo et al., 1990). Accordingly, IL-6
Animalsprotected mice against LPS toxicity in vivo (Barton and
Male IL-6 2/2 and 1/1 mice were obtained by gene targeting asJackson, 1993). The results presented in this study were
described (Poli et al., 1994). Procedures involving animals were
therefore unexpected because both in vitro and in vivo conducted in compliance with national and international laws and
evidence presented here indicates that the cytokine policies (EEC Council Directive 86/609, OJ L 358, 1, December 12,
plays instead a positive role in local inflammatory reac- 1987; Italian Legislative Decree 116/92, Gazzetta Ufficiale della Re-
pubblica Italiana number 40, February 18, 1992; National Institutestions by amplifying leukocyte recruitment.
of Health Guide for the Care and Use of LaboratoryAnimals, NationalThe effect of combined IL-6 and sIL-6R on EC was
Institutes of Health publication number 85-23, 1985).considerably specific. IL-6 and sIL-6R induced MCP-1,
MCP-3, and the C-X-C chemokine IL-8, as well as IL-6
Air Pouch
itself. Moreover, using appropriate reference agents as The air pouch model of local inflammation was performed according
positive controls, combined IL-6 and sIL-6R were not to Edwards et al. (1981). In brief, mice were anesthetized with ether
mitogenic for HUVEC and did not induce E-selectin, and subcutaneous dorsal pouches were created by injection of 5
ml of sterile air. After 3 days, the pouches were reinjected with 3VCAM-1, PAF, NOS, or procoagulant activity. In con-
ml of air. On day 6, 1 ml of 1% iota carrageenan (Sigma, St. Louis,trast, IL-6±IL-6R complexes augmented ICAM-1 expres-
MO) in sterile saline, 20 ng of human IL-1b (DompeÂ , L'Aquila, Italy),sion in HUVEC. Hence, the functional program activated
or 1 mg of human IL-8 in 1 ml of sterile 0.5% carboxymethylcellulose
in EC by gp130 triggering differs considerably from the (CMC) was injected into the pouches. The corresponding controls
set of functions induced by the proinflammmatory cyto- received sterile saline or 0.5% CMC. In the experiments with anti-
kines IL-1 and TNF or by other agents such as IL-4 and IL-6R MAb (15A7, CLB, Amsterdam, The Netherlands; Vink et al.,
1990), the antibody or an irrelevant anti-IL-4 MAb (11B11, ATCC;IL-13 (Colotta et al., 1992; Sironi et al., 1994; Rollins and
100 mg per mouse) was injected intravenously 24 hr before IL-1. AtPober, 1991; Mantovani et al., 1992).
different times after treatment, the animals were anesthetized andEC produce copious amounts of IL-6 in response to
the pouches were washed with 1 ml of saline. The lavage fluid was
a variety of signals, including microbial products (Jirik immediately cooled on ice, the volume was recorded, and 50 ml was
et al., 1989), IL-1 and TNF (Sironi et al., 1989; Jirik et al., used for the count of total leukocytes after staining with erythrosine.
1989), hypoxia (Yan et al., 1995), and other cytokines The remaining exudate was centrifuged at 5000 rpm for 10 min at
48C, and the supernatant was stored at 2208C until use.such as IL-4, IL-13, and oncostatin M (Howells et al.,
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Production of MCP-1 from Mouse Aortic Vascular Tissue (Amersham, Buckinghamshire, United Kingdom). IP-10 was mea-
sured by radioimmunoassay (courtesy of Dr. M. Cassatella). IL-6Mice were injected intravenously with 1 mg of IL-1b (DompeÂ ). After
4 hr, 1 cm of the abdominal aorta was cut, rinsed extensively with was measured as hybridoma growth factor (HGF) activity on the
7TD1 cell line, obtained through the courtesy of Dr. J. Van Snick,saline to remove all blood, and incubated for 24 hr in 1 ml of RPMI.
MCP-1 production was measured 24 hr later by a commercial ELISA as described (Sironi et al., 1989). MCP-1 levels in mouse air pouch
exudates were evaluated by a specific sandwich ELISA (Benfer-(Benfer-Sheller, Milan, Italy) and expressed as nanograms per milli-
liter. Scheller, Milan, Italy), with a sensitivity is 40 pg/ml. Mouse TNF was
measured by cytotoxicity on L929 cells in the presence of 1 mg/ml
of actinomycin D, as previously described (Aggarwal et al., 1985)Cell Culture Media and Reagents
using recombinant TNF as a standard. Prostaglandin E2 was mea-The following reagents were used for culture of cells: pyrogen-free
sured by a commercial ELISA kit (Amersham).saline for clinical use (S.A.L.F., Bergamo, Italy); pyrogen-free dis-
tilled water (S.A.L.F.); E199 medium and RPMI 1640 (103 concen-
Other EC Functionstrated; Biochrom KG, Berlin, FederalRepublic of Germany); penicillin
Expression of adhesion molecules as studied by flow cytometryand streptomycin for clinical use (Farmitalia, Milan, Italy); aseptically
using a FACStar apparatus analyzing 10,000 events (Becton Dickin-collected fetal calf serum (FCS) (Hyclone Laboratory, Logan, UT).
son, San Jose, CA) (Jonjic et al., 1992). Expression of adhesionAll reagents contained less than 0.125 EU/ml of endotoxin as
molecules was also studied on monolayers of EC in 0.32 cm2 wellschecked by the limulus amebocyte lysate assay (Microbiologi-
using an ELISA assay with a rabbit anti±mouse immunoglobulincal Associates, Walkersville, MD). 3-(4,5-dimethilthiazol-2-yl)-2,5-
antiserum conjugate with horseradish peroxidase. Procoagulant ac-diphenyl-tetrazolium bromide (MTT) was purchased from Sigma.
tivity was evaluated in the cell extract after 4 hr of incubation with
stimuli (Dejana et al., 1987). To assess proliferative activity, noncon-
Cytokines and Antibodies fluent EC (3 3 103 in 0.32 cm2) were kept overnight in M199 plus
The following human recombinant cytokines were used: IFNg (Rous- 10% FCS. The wells were then washed, and 200 ml of M199 plus
sel Uclaf, Paris, France), IL-1b (DompeÁ ; specific activity, 107 U/mg), 5% FCS and stimuli were added. After 3 days, the number of cells
TNFa (Basf knoll, Ludwighafen, Federal Republic of Germany; spe- was assessed by the MTT colorimetric assay.
cific activity 6.6 3 106 U/mg), basic FGF (Dr. M. Presta, University PAF production was measured in EC at the first passage, stimu-
of Brescia, Italy), IL-8 (Dainippon, Osaka, Japan), MCP-1 (PeproTech lated in M199 containing 0.25% BSA (low level of LPS). Cell-associ-
Inc., Rocky Hill, NJ), MCP-3 (Dr. A. Minty, Sanofi Elf Bio Recherches, ated PAF was extracted by thin-layer chromatography as previously
LabeÁ ge, France), rC5a (Dr. H. S. Showell, Pfizer Central Research, described and quantified by a biological assay as washed rabbit
Groton, CT). EAMS (endotoxin-inactivated mouse serum) was ob- platelet aggregation (Bussolino et al., 1988). For NOS activity, tryp-
tained as previously described (Boetcher and Meltzer, 1975). IL-6 sinized cells were resuspended in 1 ml of 20 mM N-2-hydroxythyl-
and the generation of the human IL-6 mutants D-6 and Sant7 have piperazine-N9-2-ethansulfonic acid (HEPES) (pH 7.2) containing 0.5
been described elsewhere (Toniatti et al., 1996; Sporeno et al., 1996). mM ethylendiamineteteaacetic acid (EDTA) and 1 mM dithiothreitol.
Both proteins were purified as described previously (Toniatti et al., Cells were lysed by sonication in ice bath (two pulses of 12 s, 100
1996). Production of sIL-6R was as follows: the conditioned super- W). NOS activity was measured by the conversion of arginine to
natant of clone CsRh14, a CHO cell stable transformant constitu- citrulline under Vmax conditions. Lysate (100 ml containing 200 mg oftively expressing a soluble form (amino acids 1±323) of human IL- protein) was incubated for 15 min at 378C with 2.5 mCi of [3H]arginine
6R (Sporeno et al., 1994), grown in serum-free medium, was used (Amersham) in the presence of 5 ml of 40 mM NADPH and 7.5 ml
as a source of sIL-6R; a serum-free supernatant from CHO was of 20 mM CaCl2. At the end of incubation, the reaction was stoppedused as control, thereafter reported as SN. Other MAbs used in this by adding 2 ml of cold 20 mM HEPES buffer (pH 6.0) containing
study were obtained through the courtesy of the following people: 2 mM EDTA. [3H]citrulline was separated by [3H]arginine by ionic
anti-VCAM-1, clone B9 (IgG1) (Dr. J. Harlan, University of Washing- exchange chromatography using 2 ml Dowex 50X8-200 resin equili-
ton, Seattle, WA); anti-E-selectin (clone 13D5; obtained from British brated with 20 mM HEPES buffer (pH 6.0). [3H]citrulline was eluted
Biotechnology, Ltd., Oxford, United Kingdom); anti-ICAM-1 clone by step gradient with 4 ml of bidistilled water and counted in a
CL 207.14 (Dr. S. Ferrone, New York Medical College, Valhalla, NY). Packard b-counter (Ghigo et al., 1995).
As irrelevant antibody, anti-IFGCP (IgG1) produced in our laboratory
by a hybridoma obtained from ATCC was used.
Migration Assay
Thioglycollate-elicited peritoneal exudate cells recovered after 24
Cells hr (PMN) or after 5 days (macrophages) were used as a source of
Human EC were obtained from umbilical veins (HUVEC) and cultured migrating mouse phagocytes. A microchemotaxis assay was used
as described in detail in a previous report (Allavena et al., 1991). as previously described (Luini et al., 1994). We seeded 27 ml of
We routinely used confluent cells at the second to sixth passage chemoattractant diluted in RPMI 1640 with 1% FCS in the lower
maintained in E199 medium with 20% FCS, supplemented with en- compartment of the chemotaxis chamber (Nucleopore Corp., Pleas-
dothelial cell growth supplement (ECGS; 50 mg/ml; Collaborative anton, CA) and 50 ml of cell suspension (4 3 106 per milliliter) in the
Research Inc., Lexington, MA) and heparin (100 mg/ml; Sigma). U937 upper compartment. The two compartments were separated by a
cells were cultured in RPMI 1640 with 10% FCS and split every 3 5 mm pore size PVP (for macrophages) or PVP-free (PMN) membrane
days. EC were also obtained from surgical specimens of iliac arteries (Nucleopore). Chambers were incubated at 378C in air with 5% CO2
or from foreskin (Van Hinsbergh et al., 1987). for 4 hr (macrophages) or 50 min (PMN). At the end of the incubation,
filters were removed, fixed, and stained with Diff-Quik (Baxter s.p.a.,
Rome, Italy). We counted migrated cells in five high poweroil-immer-Induction and Measurement of Cytokines
sion (three replicates per point) fields.Confluent EC (2 3 104 in 0.32 cm2) were kept overnight in M199 plus
20% FCS plus ECGS and heparin. Medium was then discarded, and
200 ml of M199 plus 20% FCS and stimuli were added. After 24 hr, Northern Blot Analysis
Northern blot analysis was performed according to standard proce-supernatants were harvested and kept at 2208C until measurement
of cytokines was performed. In the experiments in which IL-6 was dures. Total RNA was isolated by the guanidine isothiocyanate
method (Chirgwin et al., 1979). Total RNA (10 mg) was analyzed bymeasured, after the 24 hr of incubation with stimuli, the supernatant
was discarded, the wells were then washed, and 200 ml of M199 electrophoresis through 1% agarose±formaldehyde gels, followed
by Northern blot transfer to Gene Screen Plus sheets (New Englandplus 20% FCS without stimuli was added prior to a further 24 hr of
culture. Human MCP-1 was determined using a recently developed Nuclear, Boston, MA). The probes were as follows: FBIL-8, con-
taining a 800 bp fragment of human IL-8 cDNA cloned in the EcoRIsandwich ELISA, with a sensitivity of 30 pg/ml (Peri et al., 1994).
IL-8 was measured by ELISA using a polyclonal rabbit antiserum site of pBluescript, as described (Introna et al., 1993); MCAF, con-
taining a 700 bp fragment of human MCP-1 cDNA cloned in the PstIand MAb (gift of Dr. I. Lindley, Sandoz, Wien, Austria) as described
(Martich et al., 1991). Rantes and MIP-1a were measured by ELISA site of pBR322 plasmid, as described (Furutani et al., 1989); T7-
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80-5, containing a 800 bp fragment of human gp80 cDNA cloned in Interleukin-6 functions as an intracellular growth factor in hairy cell
leukemia in vitro. J. Clin. Invest. 92, 2346±2352.the EcoRI±ClaI site; and CHOGP130 cDNA containing a 1200 bp
fragment of human gp130 cDNA cloned in the EcoRI±HincII site. Biondi, A., Rossi, V., Bassan, R., Barbui, T., Bettoni, S., Sironi, M.,
MCP-1 (Sica et al., 1990), MCP-3 (Minty et al., 1993; Opdenakker Mantovani, A., and Rambaldi, A. (1989). Constitutive expression of
et al., 1993), and b-actin have been described previously as probes the interleukin-6 gene in chronic lymphocytic leukemia. Blood 73,
for expression studies. The inserts were in all cases gel purified 1279±1284.
after digestion and labeled by the Megaprime DNA labeling system
Boetcher, D.A., and Meltzer, M.S. (1975). Mouse mononuclear cell(Amersham) with [a-32P]dCTP (3000 Ci/mmol; Amersham). Mem-
chemotaxis: description of system. J. Natl. Cancer Inst. 54, 795±799.branes were pretreated and hybridized in 50% formamide (Merck,
Brown, T.J., Rowe, J.M., Liu, J.W., andShoyab, M. (1991). RegulationRahway, NJ) with 10% dextran sulfate (Sigma), washed twice with
of IL-6 expression by oncostatin M. J. Immunol. 147, 2175±2180.23 SSC (13 SSC: 0.15 mol/l sodium chloride, 0.015 mol/l sodium
citrate) and 1% sodium dodecil sulfate (SDS, Merck) at 608C for 30 Bussolino, F., Camussi, G., and Baglioni, C. (1988). Synthesis and
min, and finally washed twice with 0.13 SSC at room temperature release of platelet-activating factor by human vascular endothelial
for 30 min. Membranes were exposed for 12±24 hr at 2808C with cells treated with tumor necrosis factor or interleukin 1a. J. Biol.
intensifying screens. RNA transfer to membranes was checked by Chem. 263, 11856±11861.
UV irradiation, as shown in each figure. Densitometric analysis of Campbell, I.L., Abraham, C.R., Masliah, E., Kemper, P., Inglis, J.D.,
autoradiographic signals was performed with a scanning densito- Oldstone, M.B., and Mucke, L. (1993). Neurologic disease induced
metric apparatus (Hoeper, San Francisco, CA). in transgenic mice by cerebral overexpression of interleukin 6. Proc.
Natl. Acad. Sci. USA 90, 10061±10065.
Nuclear Extract Preparation and EMSA
Campbell, I.L., Hobbs, M.V., Dockter, J., Oldstone, M.B., and Allison,Nuclear extracts from human EC were prepared as described (Sal-
J. (1994). Islet inflammation and hyperplasia induced by the pancre-vati et al., 1995). For EMSA, nuclear extracts were incubated with
atic islet-specific overexpression of interleukin-6 in transgenic mice.a 32P-end-labeled double-stranded oligonucleotide corresponding
Am. J. Pathol. 145, 157±166.to the high affinity form of the serum-inducible element (SIE) of the
Chirgwin, J.M., Przybyla, A.E., MacDonald, R.J., and Rutter, W.J.c-fos promoter (Zhong et al., 1994), and the DNA±protein complexes
(1979). Isolation of a biologically active ribonucleic acid from sourceswere resolved as described (Salvati et al., 1995).
enriched in ribonuclease. Biochemistry 18, 5294±5300.
Statistical Analysis Colotta, F., Sironi, M.,Borre, A., Luini, W., Maddalena, F., and Manto-
Significance was assessed by Student's t test and Duncan's test vani, A. (1992). Interleukin 4 amplifies monocyte chemotactic protein
for multiple comparisons. and interleukin 6 production by endothelial cells. Cytokine 4, 24±28.
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